Message
We are committed to comprehensively supporting the growth and success of our clients in the life sciences industry worldwide.
Our mission is to ensure that promising seeds of drug discovery and medical technologies, which may have been overlooked, reach more patients as innovative new drugs and medical advancements.
Yoshiharu Asanuma
President & CEO
At Gemseki Investment Inc., we establish investment limited partnerships with our company as the general partner,
actively providing funding through strategic investments in venture companies engaged in pharmaceutical and medical device research and development.
Meanwhile, the Gemseki Division of our parent company, Shin Nippon Biomedical Laboratories, Ltd. (SNBL),
offers strong support for business development activities that are crucial for the growth of venture companies and academic institutions.
These activities include building partnerships and facilitating licensing efforts.
The primary goal of both initiatives is to support the growth and value enhancement of venture companies and academia,
which often operate with limited financial and human resources. We seek to uncover promising but yet-to-be-discovered seeds of drug discovery and technology
from around the world, refining them like "raw gems" and transforming them into valuable new drugs and medical devices—true "jewels" in the industry.
By fostering the creation of innovative pharmaceuticals and medical devices and supporting their growth,
we have established a one-stop support system as part of the SNBL Group.
Through this, we aim to contribute to the advancement of global healthcare.
